ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 565,59
0,24%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. XORTX Therapeutics Inc (XRTX)

  7. XORTX Therapeutics Inc (XRTX) Actualités

XRTX XORTX Therapeutics Inc

2,93
0,34 (13,13%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
XORTX Therapeutics Inc XRTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,34 13,13% 2,93 22:59:59
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,75 2,5301 3,00 2,93 2,59
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
22/4/202413:00GLOBEXORTX Announces Publication of Key Research in ADPKD
08/4/202413:30GLOBEXORTX Welcomes New Member to the Board of Directors
08/4/202413:00GLOBEXORTX Announces Participation in Spring 2024 Investor..
27/3/202410:00GLOBEXORTX Announces New Clinical Advisory Board Member
19/3/202410:00GLOBEXORTX Highlights Achievements of 2023 and Preparation for..
11/3/202412:00GLOBEXORTX Reprices Warrants Issued in Connection with Previous..
04/3/202413:00GLOBEXORTX Finalizes $2.7 Million Prospectus Supplement and..
15/2/202413:00GLOBEXORTX Raises $2.5 Million Under Prospectus Supplement and..
02/2/202402:46GLOBEXORTX Files an Amended and Restated Prospectus Supplement..
15/1/202413:00GLOBEXORTX Announces $2 Million Public Offering
03/1/202413:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/1/202413:00GLOBEXORTX Submits a New Patent for the Treatment of Chronic..
02/1/202414:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/1/202413:00GLOBEXORTX Welcomes New Member to the Board of Directors
30/11/202322:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/11/202313:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/11/202313:30GLOBEXORTX Announces US ATM Offering
30/11/202303:57EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/11/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202313:00GLOBEXORTX Meets Nasdaq Continued Listing Requirements
13/11/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/11/202313:00GLOBEXORTX Clarifies Timing for Share Consolidation
08/11/202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202323:00GLOBEXORTX Announces Share Consolidation
02/11/202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202312:00GLOBEXORTX Sponsored Study Presented at the American Society of..
27/10/202323:30GLOBEXORTX Announces Results of Special Meeting of Shareholders
25/10/202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/10/202323:00GLOBEXORTX Announces Date for Rescheduled Special Meeting of..
25/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/10/202313:00GLOBEXORTX Announces Rescheduling of Special Meeting of..
12/10/202313:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202313:00GLOBEXORTX Reports that Independent Proxy Firm, ISS, Recommends..
04/10/202319:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202313:00GLOBEXORTX Calls Special Meeting of Shareholders
28/9/202313:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/9/202313:00GLOBEXORTX Sponsored Study Selected for Presentation at the..
12/9/202321:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202313:00GLOBEXORTX Announces Participation at Upcoming Investor..
07/9/202314:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/9/202313:00GLOBEXORTX Joins the Kidney Foundation and Kidney March
29/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202313:00GLOBEXORTX Submits Orphan Drug Designation Application to the..
25/8/202312:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202322:42EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202322:40EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
04/8/202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/8/202323:00GLOBEXORTX Appoints Chief Financial Officer

Dernières Valeurs Consultées

NASDAQ
XRTX
XORTX Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés